1. Scrip

Rybelsus, Other Treatment Improvements For Chronic Disease Have OptumRx’s Attention

 
• By Cathy Kelly

UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and migraine, as well as luspatercept for beta thalassemia, in its latest pipeline report.

Businessman with binoculars. - Image
Horizon Scanning At OptumRx

[UnitedHealthCare]’s pharmacy benefit manager OptumRx Inc. flags Novo Nordisk AS’s just-approved oral semaglutide for type 2 diabetes, Rybelsus, and a handful of other novel or improved treatments for chronic conditions as near-term launches with potentially significant economic impacts in its latest Pipeline Insights Report.

The Q3 report, which is the second to be issued by the major PBM, offers a snapshot of potentially high-cost drugs payers are expecting to reach the market in the coming months. Its focus on chronic-use treatments contrasts with the first OptumRx pipeline report, which highlighted drugs for rare diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.